Abstract
Background Dysarthria frequently occurs as a result of stroke and adversely impacts speech sound production, making it more difficult for the listener to understand what the person with dysarthria is attempting to communicate. This in turn may lead to social isolation, depression, and increased cost of care. Some studies have underscored the importance of respiratory muscle strengthening as it relates to improvement of speech intelligibility, However, the benefits of respiratory muscle training on dysarthric speech following stroke have not been explored. This retrospective investigation examined the effects of a combined Respiratory Muscle Training (cRMT) protocol upon speech intelligibility in persons post single cerebrovascular accident (CVA).
Methods The clinical data of 10 patients who requested speech therapy at a pro bono outpatient clinic for the diagnosis and treatment of dysarthria following a single stroke was utilized for this study. The intervention group was treated with three 5-minute sessions with cRMT each day for 28 consecutive days. The control group received no cRMT and no other therapeutic exercise intervention during the time period. Respiratory function and speech intelligibility were assessed pre- and post-intervention in terms of peak expiratory flow, subject self-perception of intelligibility, and word level intelligibility.
Results After 28 days of cRMT, the intervention group exhibited significant gains compared to the control group in peak expiratory flow (PEF) (IG: 73.12% vs CG: 4.66%), Self-Perception of Intelligibility (IG: 72.38% vs CG: 0.83%), and the word task of the Assessment of Intelligibility of Dysarthric Speech (AIDS) (IG: 43.92% vs. CG: 0%).
Conclusion These retrospective data demonstrate cRMT is a feasible and effective treatment for improving breath support and speech intelligibility in persons with dysarthric speech after single stroke.
Competing Interest Statement
CG declares no conflict of interest. NB serves as independent Chief Scientist for PN Medical. RJA declares no conflict of interest. TM declares no conflict of interest.
Clinical Trial
This is not a prospective trial, therefore it was conducted under an IRB waiver granted by Western IRB.
Funding Statement
No funding has been received for this study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Western IRB 1019 39th AVE SE, Suite 120 Puyallup WA 98374/2115 Phone: +1 360 252/2500 www.wirb.com
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
robert.arnold{at}sba.net.co
chris.gaskill{at}gmail.com
trkmid{at}gmail.com
This revision contains added figures for clarification of individual changes in the intervention and control groups.
Data Availability
All data can be made available upon request from SBA, LLC.
